Biogen Re-Ups With Ionis In Search Of A Neuroscience 'Innovation Engine'

New 10-year collaboration, the sixth between the two firms, will attempt to bring seven antisense candidates for neurological indications to the clinic in the next two years. Biogen pays $1bn up front, split between cash and Ionis equity.